Half-year report · Q2

Period2024-10-01 → 2025-03-31
Filed2025-05-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥17.8bn2024-10-01 → 2025-03-31Cons.Net sales
Revenue¥32.2bn2023-10-01 → 2024-09-30Cons.Net sales (5-year summary)
Revenue¥16.6bn2023-10-01 → 2024-03-31Cons.Net sales
Operating income¥325m2024-10-01 → 2025-03-31Cons.Operating income
Operating income¥276m2023-10-01 → 2024-03-31Cons.Operating income
Ordinary income¥355m2024-10-01 → 2025-03-31Cons.Ordinary income
Ordinary income¥408m2023-10-01 → 2024-09-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥302m2023-10-01 → 2024-03-31Cons.Ordinary income
Profit before tax¥400m2024-10-01 → 2025-03-31Cons.Income before income taxes
Profit before tax¥314m2023-10-01 → 2024-03-31Cons.Income before income taxes
Net income (owners)¥269m2024-10-01 → 2025-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥237m2023-10-01 → 2024-09-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥211m2023-10-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income¥273m2024-10-01 → 2025-03-31Cons.Profit loss
Net income¥213m2023-10-01 → 2024-03-31Cons.Profit loss
Total assets¥18.5bnat 2025-03-31Cons.Assets
Total assets¥17.2bnat 2024-09-30Cons.Assets
Total assets¥19.8bnat 2024-03-31Cons.Total assets (5-year summary)
Total liabilities¥10.8bnat 2025-03-31Cons.Liabilities
Total liabilities¥9.7bnat 2024-09-30Cons.Liabilities
Net assets / equity¥7.7bnat 2025-03-31Cons.Net assets
Net assets / equity¥7.5bnat 2024-09-30Cons.Net assets
Net assets / equity¥7.6bnat 2024-03-31Cons.Net assets (5-year summary)
Cash and deposits¥1.5bnat 2025-03-31Cons.Cash and deposits
Cash and deposits¥764mat 2024-09-30Cons.Cash and deposits
Cash & equivalents¥1.5bnat 2025-03-31Cons.Cash and cash equivalents
Cash & equivalents¥745mat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.2bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.1bnat 2023-09-30dCons.Cash and cash equivalents
Operating cash flow¥674m2024-10-01 → 2025-03-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.0bn2023-10-01 → 2024-09-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥226m2023-10-01 → 2024-03-31Cons.Net cash provided by used in operating activities
Investing cash flow¥62m2024-10-01 → 2025-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥108m2023-10-01 → 2024-09-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥54m2023-10-01 → 2024-03-31Cons.Net cash provided by used in investment activities
Financing cash flow¥6m2024-10-01 → 2025-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥210m2023-10-01 → 2024-09-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥83m2023-10-01 → 2024-03-31Cons.Net cash provided by used in financing activities
EPS (basic)¥298.42024-10-01 → 2025-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥263.542023-10-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥233.862023-10-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio40.9%at 2025-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio43.0%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio38.2%at 2024-03-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segmentrevenue2024-10-01 → 2025-03-31¥1.5bn
jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segmentrevenue external2024-10-01 → 2025-03-31¥1.5bn
jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segmentrevenue2024-10-01 → 2025-03-31¥9.1bn
jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segmentrevenue external2024-10-01 → 2025-03-31¥9.1bn
jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segmentrevenue2024-10-01 → 2025-03-31¥7.2bn
jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segmentrevenue external2024-10-01 → 2025-03-31¥7.2bn
—segment totalrevenue2024-10-01 → 2025-03-31¥17.8bn
—segment totalrevenue external2024-10-01 → 2025-03-31¥17.8bn
jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segmentrevenue2023-10-01 → 2024-03-31¥1.2bn
jpcrp040300-q2r_E02810-000Academia Life Science Sales Groupreportable segmentrevenue external2023-10-01 → 2024-03-31¥1.2bn
jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segmentrevenue2023-10-01 → 2024-03-31¥8.3bn
jpcrp040300-q2r_E02810-000Industry Sales Groupreportable segmentrevenue external2023-10-01 → 2024-03-31¥8.3bn
jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segmentrevenue2023-10-01 → 2024-03-31¥7.1bn
jpcrp040300-q2r_E02810-000Medical Sales Groupreportable segmentrevenue external2023-10-01 → 2024-03-31¥7.1bn
—segment totalrevenue2023-10-01 → 2024-03-31¥16.6bn
—segment totalrevenue external2023-10-01 → 2024-03-31¥16.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 508
ItemContextValueUnit
Number of shares heldCurrentQuarterInstant_No2MajorShareholdersMember81300
Shareholding ratioCurrentQuarterInstant_No2MajorShareholdersMember0.090
Number of shares heldCurrentQuarterInstant_No3MajorShareholdersMember52940
Shareholding ratioCurrentQuarterInstant_No3MajorShareholdersMember0.059
Number of shares heldCurrentQuarterInstant_No4MajorShareholdersMember50800
Shareholding ratioCurrentQuarterInstant_No4MajorShareholdersMember0.056
Number of shares heldCurrentQuarterInstant_No5MajorShareholdersMember43060
Shareholding ratioCurrentQuarterInstant_No5MajorShareholdersMember0.048
Number of shares heldCurrentQuarterInstant_No6MajorShareholdersMember30300
Shareholding ratioCurrentQuarterInstant_No6MajorShareholdersMember0.034
Number of shares heldCurrentQuarterInstant_No7MajorShareholdersMember30200
Shareholding ratioCurrentQuarterInstant_No7MajorShareholdersMember0.034
Number of shares heldCurrentQuarterInstant_No8MajorShareholdersMember22000
Shareholding ratioCurrentQuarterInstant_No8MajorShareholdersMember0.024
Number of shares heldCurrentQuarterInstant_No9MajorShareholdersMember20400
Shareholding ratioCurrentQuarterInstant_No9MajorShareholdersMember0.023
Number of shares heldCurrentQuarterInstant_No10MajorShareholdersMember19790
Shareholding ratioCurrentQuarterInstant_No10MajorShareholdersMember0.022
Number of shares heldCurrentQuarterInstant440390
Shareholding ratioCurrentQuarterInstant0.489
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember59000
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember899700
Number of voting rights issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember8997
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember1300
Number of shares issued shares voting rightsCurrentQuarterInstant960000
Number of voting rights issued shares voting rightsCurrentQuarterInstant8997
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row1Member59000
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row1Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member59000
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.061
Number of shares held in own name treasury shares etcCurrentQuarterInstant59000
Number of shares held in others names treasury shares etcCurrentQuarterInstant-
Total number of shares held treasury shares etcCurrentQuarterInstant59000
Shareholding ratio treasury shares etcCurrentQuarterInstant0.061
Cash and depositsPrior1YearInstant763789000JPY
Cash and depositsCurrentQuarterInstant1506607000JPY
Notes and accounts receivable trade and contract assetsPrior1YearInstant9078832000JPY
Notes and accounts receivable trade and contract assetsCurrentQuarterInstant9409999000JPY
Electronically recorded monetary claims operating caPrior1YearInstant332501000JPY
Electronically recorded monetary claims operating caCurrentQuarterInstant381963000JPY
MerchandisePrior1YearInstant1057176000JPY
MerchandiseCurrentQuarterInstant1374775000JPY
Lease investment assets caPrior1YearInstant94789000JPY
Lease investment assets caCurrentQuarterInstant84415000JPY
Other caPrior1YearInstant370760000JPY
Other caCurrentQuarterInstant318811000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-09-30pass rounding
balance sheet identityconsolidated 2025-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net assetsconsolidated 2025-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-10-01/2025-03-31pass
statement vs summary · operating cash flowconsolidated 2023-10-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2024-10-01/2025-03-31pass
statement vs summary · revenueconsolidated 2023-10-01/2024-03-31pass
statement vs summary · revenueconsolidated 2024-10-01/2025-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass
statement vs summary · total assetsconsolidated 2025-03-31pass